Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquitin-protein ligase E3A (UBE3A) is an enzyme that plays a central role in the ubiquitin–proteasome system, responsible for tagging proteins with ubiquitin for degradation. It is crucial for neuronal function, synaptic plasticity, and overall cellular homeostasis. Loss-of-function mutations in the maternally inherited UBE3A gene cause Angelman syndrome, while rare gain-of-function variants are associated with autism and intellectual disability. UBE3A also acts as a transcriptional coactivator. It regulates viral pathogenesis by targeting key viral proteins for degradation.
Catalyzes the formation of K48-linked polyubiquitin chains on substrate proteins, targeting them for proteasomal degradation. Functions as a transcriptional coactivator for steroid hormone receptors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin-protein ligase E3A (UBE3A).